Adriano Salaroli

677 total citations
29 papers, 251 citations indexed

About

Adriano Salaroli is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Adriano Salaroli has authored 29 papers receiving a total of 251 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 18 papers in Genetics and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Adriano Salaroli's work include Acute Myeloid Leukemia Research (14 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Chronic Myeloid Leukemia Treatments (10 papers). Adriano Salaroli is often cited by papers focused on Acute Myeloid Leukemia Research (14 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Chronic Myeloid Leukemia Treatments (10 papers). Adriano Salaroli collaborates with scholars based in Italy, Belgium and United States. Adriano Salaroli's co-authors include Massimo Breccia, Giuseppina Loglisci, Roberto Latagliata, Michelina Santopietro, Giuliana Alimena, Alessandra Serrao, Giuliana Alimena, Luigi Petrucci, Laura Cannella and Vincenzo Federico and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Adriano Salaroli

26 papers receiving 249 citations

Peers

Countries citing papers authored by Adriano Salaroli

Since Specialization

Citations

This map shows the geographic impact of Adriano Salaroli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adriano Salaroli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adriano Salaroli more than expected).

Fields of papers citing papers by Adriano Salaroli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adriano Salaroli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adriano Salaroli. The network helps show where Adriano Salaroli may publish in the future.

Co-authorship network of co-authors of Adriano Salaroli

This figure shows the co-authorship network connecting the top 25 collaborators of Adriano Salaroli. A scholar is included among the top collaborators of Adriano Salaroli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adriano Salaroli. Adriano Salaroli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data 2024 ·Patient Preference and Adherence ·(unknown), (unknown), Adriano Salaroli, Dominique Bron, Philippe Lewalle, (unknown), Hélène A. Poirel, Fati Kirakoya‐Samadoulougou	0
2	Measurable residual disease assessment prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndromes: a 20-year monocentric study 2024 ·Annals of Hematology ·(unknown), Adriano Salaroli, (unknown), Marianne Paesmans, (unknown), Pierre Heimann, Sébastian Wittnebel, Philippe Lewalle	3
3	Surprising erythrocytosis resolution after myomectomy: myomatous erythrocytosis syndrome 2023 ·European Journal of Case Reports in Internal Medicine ·(unknown), Philippe Lewalle, (unknown), Adriano Salaroli	1
4	Biomarkers for Early Diagnosis of Hemophagocytic Lymphohistiocytosis in Critically Ill Patients 2021 ·Journal of Clinical Immunology ·France Debaugnies, Bhavna Mahadeb, Carole Nagant, Nathalie Meuleman, David De Bels, Fleur Wolff, Philippe Gottignies, Adriano Salaroli, Patricia Borde, M. Voué, Francis Corazza	28
5	Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions 2020 ·Current Opinion in Oncology ·Adriano Salaroli, (unknown), Dominique Bron, Philippe Lewalle	3
6	Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia 2017 ·Leukemia Research ·Francesca Romana Mauro, Fortunato Morabito, Iolanda Donatella Vincelli, Luigi Petrucci, (unknown), Adriano Salaroli, Giuseppina Uccello, Annamaria Petrungaro, Francesca Ronco, Sara Raponi, Mauro Nanni, Antonino Neri, Manlio Ferrarini, (unknown), Robin Foà, Massimo Gentile	19
7	Reappraising the timing of transplant for indolent non-Hodgkin lymphomas 2016 ·Expert Review of Hematology ·Saveria Capria, Walter Barberi, Salvatore Perrone, Antonietta Ferretti, Adriano Salaroli, Giorgia Annechini, Gianna Maria D’Elia, Robin Foà, Alessandro Pulsoni	0
8	Management of elderly and unfit patients with chronic lymphocytic leukemia 2016 ·Expert Review of Hematology ·Francesca Romana Mauro, Adriano Salaroli, Maria Caputo, Gioia Colafigli, Luigi Petrucci, (unknown), Antonietta Ferretti, Anna Guarini, Robin Foà	4
9	Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response 2015 ·Leukemia & lymphoma ·Roberto Latagliata, Angela Romano, Marco Mancini, Massimo Breccia, Ida Carmosino, Federico Vozella, (unknown), (unknown), Federico De Angelis, Luigi Petrucci, Alessandra Serrao, Matteo Molica, Adriano Salaroli, Daniela Diverio, Giuliana Alimena	9
10	Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib 2013 ·Cancer Letters ·Massimo Breccia, Giuseppina Loglisci, Adriano Salaroli, Alessandra Serrao, Marco Mancini, Daniela Diverio, Roberto Latagliata, Giuliana Alimena	13
11	Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a “Real-life” Patient Population With Chronic Myelogenous Leukemia? 2013 ·Blood ·Roberto Latagliata, Ida Carmosino, Federico Vozella, (unknown), Giuseppina Loglisci, Michelina Santopietro, Adriano Salaroli, Angela Romano, (unknown), (unknown), Alessandra Serrao, Daniela Diverio, Mauro Nanni, Marco Mancini, Agostino Tafuri, Massimo Breccia, Giuliana Alimena	0
12	Systematic review of dasatinib in chronic myeloid leukemia 2013 ·OncoTargets and Therapy ·Massimo Breccia, Adriano Salaroli, Matteo Molica, Giuliana Alimena	12
13	Deferasirox treatment for myelodysplastic syndromes: “real-life” efficacy and safety in a single-institution patient population 2012 ·Annals of Hematology ·Massimo Breccia, (unknown), Giuseppina Loglisci, Vincenzo Federico, Michelina Santopietro, Gioia Colafigli, Luigi Petrucci, Adriano Salaroli, Alessandra Serrao, Roberto Latagliata, Giuliana Alimena	24
14	Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols 2012 ·Leukemia Research ·Massimo Breccia, Clara Minotti, Roberto Latagliata, Giuseppina Loglisci, Adriano Salaroli, (unknown), Francesco Lo‐Coco	3
15	5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials 2012 ·Leukemia & lymphoma ·Massimo Breccia, Giuseppina Loglisci, Adriano Salaroli, Alessandra Serrao, Luigi Petrucci, Marco Mancini, Giuliana Alimena	11
16	Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experience 2012 ·Leukemia & lymphoma ·Massimo Breccia, (unknown), Giuseppina Loglisci, Michelina Santopietro, Adriano Salaroli, Alessandra Serrao, Roberto Latagliata, (unknown), Luigi Petrucci, Mauro Nanni, Giuliana Alimena	5
17	5′-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment 2011 ·Leukemia Research ·Massimo Breccia, Adriano Salaroli, Giuseppina Loglisci, Maurizio Martelli, Gianna Maria D’Elia, Mauro Nanni, Francesca Romana Mauro, Giuliana Alimena	2
18	LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE 2011 ·SHILAP Revista de lepidopterología ·Massimo Breccia, Corrado Girmenia, Roberto Latagliata, Giuseppina Loglisci, Michelina Santopietro, Vincenzo Federico, Luigi Petrucci, Alessandra Serrao, Adriano Salaroli, Giuliana Alimena	14
19	Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients 2010 ·Leukemia Research ·Massimo Breccia, Vincenzo Federico, Roberto Latagliata, (unknown), Gianna Maria D’Elia, Laura Cannella, Giuseppina Loglisci, Adriano Salaroli, Michelina Santopietro, Giuliana Alimena	26
20	Deferasirox Treatment Interruption in a Transfusion-Requiring Myelodysplastic Patient Led to Loss of Erythroid Response 2010 ·Acta Haematologica ·Massimo Breccia, Giuseppina Loglisci, Adriano Salaroli, Laura Cannella, Michelina Santopietro, Giuliana Alimena	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact